Abstract
Guselkumab (Tremfya™) is a human monoclonal IgG1λ antibody being developed by Janssen Biotech, Inc. that has been approved in the USA as a treatment for moderate-to-severe plaque psoriasis. Guselkumab inhibits the binding of interleukin 23 (IL-23) to its cell surface receptor, disrupting the type 17 helper T cell/IL-17 pathway. This article summarizes the milestones in the development of guselkumab leading to this first approval for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
MeSH terms
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / pharmacokinetics*
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Dose-Response Relationship, Drug
-
Drug Approval
-
Drug Compounding
-
Humans
-
Immunoglobulin G / administration & dosage
-
Immunoglobulin G / adverse effects
-
Immunoglobulin G / pharmacology*
-
Immunoglobulin G / therapeutic use
-
Interleukin-23 / antagonists & inhibitors
-
Psoriasis / drug therapy*
-
United States
-
United States Food and Drug Administration
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Immunoglobulin G
-
Interleukin-23
-
guselkumab